Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
0.8580
+0.3110 (56.86%)
At close: Aug 13, 2025, 4:00 PM
0.7919
-0.0661 (-7.70%)
After-hours: Aug 13, 2025, 7:15 PM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $6.27M in the quarter ending June 30, 2025, with 3,611.24% growth. This brings the company's revenue in the last twelve months to $6.65M, up 1,070.95% year-over-year. In the year 2024, Ovid Therapeutics had annual revenue of $566.00K with 44.39% growth.
Revenue (ttm)
$6.65M
Revenue Growth
+1,070.95%
P/S Ratio
70.86
Revenue / Employee
$289,174
Employees
23
Market Cap
61.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
Dec 31, 2020 | 12.62M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OVID News
- 11 hours ago - Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties - GlobeNewsWire
- 3 months ago - Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewsWire
- 5 months ago - Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 months ago - Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire